Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Verastem Inc.

    NASDAQ: VSTM · Real-Time Price · USD
    7.08
    -0.38 (-5.09%)
    At close: May 14, 2025, 3:59 PM
    7.16
    1.06%
    After-hours: May 14, 2025, 07:28 PM EDT
    -5.09%
    Bid 6.91
    Market Cap 364.81M
    Revenue (ttm) 10M
    Net Income (ttm) -130.64M
    EPS (ttm) -3.66
    PE Ratio (ttm) -1.94
    Forward PE -5.74
    Analyst Buy
    Ask 8.24
    Volume 2,094,938
    Avg. Volume (20D) 1,100,350
    Open 7.44
    Previous Close 7.46
    Day's Range 6.93 - 8.35
    52-Week Range 2.10 - 13.52
    Beta 0.85

    About VSTM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol VSTM
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for VSTM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Earnings Surprise

    Verastem has released their quartely earnings on May 13, 2025:
  • Revenue of $0 misses estimates by $200K, with NaN% YoY growth.
  • EPS of -0.79 misses estimates by -0.18, with 19.39% YoY growth.

    • Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 weeks ago
    +0%
    Verastem shares are trading higher after the compa... Unlock content with Pro Subscription
    6 months ago
    -20.12%
    Verastem shares are trading lower. The company presented updated data on the Avutometinib And Defactinib combo in recurrent low-grade serous ovarian cancer at IGCS 2024.
    news image

    1 day ago · businesswire.com

    Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates

    BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business ...

    news image

    6 days ago · businesswire.com

    FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

    BOSTON--(BUSINESS WIRE)---- $VSTM #FDA--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today anno...

    news image

    1 week ago · reuters.com

    U.S. FDA approves Verastem's cancer therapy

    The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer who have received prior treatment, the regulator said on Thursday.

    news image

    1 week ago · businesswire.com

    Verastem Oncology to Present at Upcoming Investor Conferences

    BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its ...

    news image

    2 weeks ago · businesswire.com

    Verastem Oncology Announces $75 million Private Placement

    BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that it h...

    news image

    4 weeks ago · zacks.com

    Top Cancer Stocks to Buy to Boost Your Portfolio's Health

    If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.

    news image

    1 month ago · seekingalpha.com

    Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination

    Verastem, Inc.'s priority review PDUFA date of avutometinib + defactinib for treatment of patients with recurrent LGSOC is expected June 30th of 2025; At this time, no FDA advisory committee to be hel...

    news image

    1 month ago · businesswire.com

    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purc...

    news image

    1 month ago · zacks.com

    Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade

    The average of price targets set by Wall Street analysts indicates a potential upside of 100.9% in Verastem (VSTM). While the effectiveness of this highly sought-after metric is questionable, the posi...

    news image

    1 month ago · businesswire.com

    Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025

    BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple ...

    Add to Watchlist